The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: a milder course?
| Autor: | Sibel Canbaz Kabay, Murat Kürtüncü, Sedat Sen, Pinar Acar, Haluk Gümüş, Murat Terzi, Dilcan Kotan, Özden Kamışlı, Ipek Gungor Dogan, Aksel Siva, Sami Omerhoca, Yusuf Tamam, Serkan Demir, Gokhan Arslan, Destan Bunul, Ahmet Kasim Kilic, Semra Mungan, Tuncay Gündüz, Belgin Petek Balci, Husnu Efendi, Melih Tutuncu, Ugur Uygunoglu, Yeşim Beckmann, Sibel Güler, Levent Sinan Bir, Serhan Sevim, Ömer Faruk Turan, Özgül Ekmekci, Mesrure Koseoglu, Rana Karabudak, Nur Yüceyar, Meltem Demirkiran, Cavid Baba, Serkan Ozakbas, Ayse Altintas, Cihat Uzunköprü, Aslı Tuncer |
|---|---|
| Přispěvatelé: | Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Şen, S., Tuncer, A., Özakbaş, S., Uzunköprü, C., Baba, C., Demir, S., Beckmann, Y., Gümüş, H., Arslan, G., Kılıç, A.K., Yüceyar, N., Turan, O.F., Tütüncü, M., Terzi, M., Acar, P., Bünül, S.D., Balcı, B.P., Bir, L.S., Köseoğlu, M., Mungan, S., Gündüz, T., Doğan, I.G., Kotan, D., Uygunoğlu, U., Ekmekçi, O., Demirkiran, M., Kamışlı O., Kabay, S.C., Tamam, Y., Ömerhoca, S., Sevim, S., Güler, S., Kürtüncü, M., Efendi, H., Karabudak, R., Şiva A., School of Medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
clinical outcome
serology Disease myelin oligodendrocyte glycoprotein myelooptic neuropathy rituximab experience Medicine azathioprine biology Medicine general and internal adult Neuromyelitis Optica General Medicine cohort analysis comorbidity female risk factor Neurology Comorbid disease Myelin oligodendrocyte glycoprotein antibody-associated disorders disease severity hospitalization medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Coronavirus Disease modifying treatment Neuromyelitis optica spectrum disorders SARS-CoV-2 complication protein deficiency Article Myelin oligodendrocyte glycoprotein coronavirus disease 2019 male Disease severity death myelin oligodendrocyte glycoprotein antibody associated disorder Internal medicine Humans controlled study human Autoantibodies Aquaporin 4 business.industry Multiple sclerosis disease association COVID-19 medical information medicine.disease major clinical study clinical feature age exposure Neuromyelitis Optica Spectrum Disorders biology.protein Myelin-Oligodendrocyte Glycoprotein Neurology (clinical) disease duration business autoantibody |
| Zdroj: | Multiple Sclerosis and Related Disorders |
| Popis: | Background: COVID-19 is a multisystemic infection with variables consequences depending on individual and comorbid conditions. The course and outcomes of COVID-19 during neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are not clearly known. Objective methods: the aim of this study was to examine the features and outcomes of COVID-19 infection in NMOSD and MOGAD patients. The patients' demographic and clinical factors, disease modifying treatment (DMT) used and disease information of COVID-19 infection were recorded. Conditions leading to hospitalization and severe exposure to COVID-19 infection were also analyzed. Results: the study included 63 patients from 25 centers. Thirty-two patients (50.8%) belong to AQP-4 seropositive group, 13 (20.6%) and 18 (28.6%) were in MOG-positive and double-seronegative groups, respectively. Risk factors for severe COVID-19 infection and hospitalization were advanced age, high disability level and the presence of comorbid disease. Disease severity was found to be high in double-seronegative NMOSD and low in MOGAD patients. No statistically significant effect of DMTs on disease severity and hospitalization was found. Conclusion: in NMOSD and MOGAD patients, advanced age, high disability and presence of comorbid disease pose risks for severe COVID-19 infection. There was no direct significant effect of DMTs for COVID-19 infection. NA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|